Document Detail


Artemisinin reduces the level of antibodies to gliadin in schizophrenia.
MedLine Citation:
PMID:  21546216     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: To investigate if adjunctive artemisinin, an anti-malarial compound with in vivo activity against Toxoplasma gondii, reduces symptoms or antibodies in schizophrenia. METHOD: N=66 outpatients with schizophrenia were randomized to receive 100mg of artemisinin twice a day or placebo for 10weeks after a 2week placebo run-in in addition to their usual psychiatric medications. Symptoms were assessed biweekly. Antibodies to toxoplasma and to gliadin, a food antigen, were assessed at the beginning and end of the trial. RESULTS: A total of 57 participants (26 in the artemisinin arm and 31 in the placebo arm) completed the 12weeks of the trial. The medication was well tolerated and there were no significant side effects associated with the treatment regimen. There was no significant difference in the change of positive, negative, general, or total PANSS symptoms between groups for all of the randomized patients or for just the completers. However, individuals in the artemisinin arm but not in the placebo arm had significant decreases in the levels of antibodies to gliadin (p<.0005, p>.2, respectively by paired t-test). Neither group had significant changes in antibodies to T. gondii. CONCLUSIONS: The study did not demonstrate clinical benefit of adjunctive artemisinin for schizophrenia symptoms. The finding of reduced levels of antibodies to gliadin in the artemisinin group merits further study.
Authors:
Faith Dickerson; Cassie Stallings; Crystal Vaughan; Andrea Origoni; Joshana Goga; Sunil Khushalani; Robert Yolken
Related Documents :
8034076 - Post-therapeutic evolution of serum chlamydial antibody titers in women with acute salp...
9015696 - Progesterone levels in preterm labor are not affected by ritodrin treatment.
15652906 - Intrauterine instillation of trichloroacetic acid is effective for the treatment of dys...
17179056 - Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, h...
8625666 - A randomized, double-blind, placebo-controlled study of lorazepam as premedication for ...
7748646 - Evaluation of the use of brief screening instruments for dementia, depression and probl...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-4
Journal Detail:
Title:  Schizophrenia research     Volume:  -     ISSN:  1573-2509     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-5-6     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8804207     Medline TA:  Schizophr Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011. Published by Elsevier B.V.
Affiliation:
Sheppard Pratt, 6501 North Charles St., Baltimore, MD 21204, United States.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increased prevalence of Chlamydophila DNA in post-mortem brain frontal cortex from patients with sch...
Next Document:  Hippocampal size in women but not men with schizophrenia relates to disorder duration.